Brittany Lovely

Senior Editor, OncLive®
Brittany Lovely is a senior editor for the OncologyLive® print publication and editor of the Miami Breast Cancer Conference® and Chemotherapy Foundation Symposium® dailies. Email: blovely@mjhassoc.com


Articles

Reshaping the Treatment Landscape for Recurrent/Metastatic Nasopharyngeal Carcinoma

May 26th 2022

In the context of checkpoint blockade in nasopharyngeal carcinoma, the results of the phase 3 RATIONALE-309 trial support earlier findings of the role immunotherapy may play for patients in the first line.

2022 ASCO Meeting Agenda Sets the Stage for the Future of Care

May 25th 2022

The 2022 American Society of Clinical Oncology Annual Meeting returns to Chicago, Illinois, with an agenda highlighting primary outcomes as well as extended follow-up data across malignancies.

Hotspot ESR1 Mutations Drive Tumor Stickiness in Metastatic Endocrine-Resistant Breast Cancer

May 24th 2022

The prevalence of ESR1 mutations in endocrine-resistant metastatic breast cancer has paved an avenue for investigators to explore their role in the promotion of metastasis.

Clinical Benefit With Elacestrant Shines Spotlight on SERDs in ER+/HER2- Breast Cancer

May 23rd 2022

A significant improvement in progression-free survival has been reported with the oral selective estrogen receptor degrader elacestrant vs standard of care treatments for patients with estrogen receptor–positive, HER2-negative breast cancer.

New Programs Unlock Patient Access to Oncology Care

May 19th 2022

Developing a system with a patient-centric focus, investigators at Yale Cancer Center and Moffitt Cancer Center initiated pilot programs to offer patients better access to care following a diagnosis of cancer.

Antegrade Administration of Mitomycin Gel Provides Safe, Effective Approach in Upper Tract Urothelial Carcinoma

May 16th 2022

Data from a retrospective analysis demonstrated that mitomycin gel was safe and effective when administered using an antegrade approach in real-world populations of patients with low-grade upper tract urothelial cancer.

Unmasking NETs Requires a Multifaceted Approach to Care

May 10th 2022

Eric Liu, MD, FACS, reviews treatment options, pitfalls of diagnoses, and the importance of involving specialists and advocates early in neuroendocrine tumors.

Evidence Grows to Support Trastuzumab Deruxtecan in Patients With HER2+ Breast Cancer and Active Brain Metastases

May 6th 2022

Nearly all patients with HER2-positive breast cancer with brain metastases who received fam-trastuzumab deruxtecan-nxki elicited benefit, according to data from a primary outcome analysis of the phase 2 TUXEDO-1 trial.

Sacituzumab Govitecan Maintains Clinical Benefit Across HER2 Expressions in TNBC

May 5th 2022

Sacituzumab govitecan-hziy maintained clinical benefit in patients with metastatic triple-negative breast cancer regardless of HER2 expression according to a post hoc analysis of the phase 3 ASCENT trial.

Match-Adjusted Comparison Shows Comparable Efficacy Outcomes for Axi-cel and Tisa-cel in Follicular Lymphoma

April 25th 2022

Results of a match-adjusted analysis of patients with follicular lymphoma treated with axicabtagene ciloleucel in ZUMA-5 trial vs those treated with tisagenlecleucel in ELARA showed a similar efficacy profile between the 2 cellular therapies.

Treatment Optimization Efforts Seek to Overcome Resistance in Advanced CML

April 15th 2022

Elias J. Jabbour, MD, and Matthew S. Davids, MD, MMSc, review data on asciminib and ponatinib in the post–second generation TKI setting for chronic myeloid leukemia that were presented at the 2021 ASH Meeting and Exposition.

JDQ443 Demonstrates Early Efficacy Signals in KRAS G12C-Mutant Solid Tumors

April 11th 2022

The novel KRAS G12C inhibitor, JDQ443, demonstrated early efficacy signals and a tolerable safety profile in initial data from the dose-escalation portion of the phase 1b/2 KontRASt-01 trial.

Matulonis’ Passion Drives Gynecologic Cancer Research Into the Next Era

April 7th 2022

Specialization in oncology research affords investigators the opportunity to dive into tumor biology and uncover unique approaches to care.

SERDs, ESR1 Mutations Dominate Updates in ER-Positive Breast Cancer

March 31st 2022

Sara A. Hurvitz, MD, FACP, led a panel of breast cancer experts—Aditya Bardia, MD, MPH; Patrick Neven, MD, PhD; and Kevin Kalinsky, MD, MS—in a review of key data from the 2021 San Antonio Breast Cancer Symposium in ER-positive breast cancer.

First Steps Down the HER3 Pathway in NSCLC Signal Early Success

March 30th 2022

Disease progression and acquired resistance to approved EGFR tyrosine kinase inhibitors have resulted in a treatment void in the third- and later-line settings for patients with non–small cell lung cancer.

Investigators Seek to Expand Treatment Options for aGVHD with Novel Anti-CD6 Agent

March 29th 2022

Corey S. Cutler, MD, MPH, FRCPC, notes the clinical benefit observed with itolizumab in EQUATE and the observations that informed the design of the phase 3 EQUATOR trial.

E-Selectin Presents a Favorable Path Forward for AML Populations

March 28th 2022

In acute myeloid leukemia, investigators are exploring novel agents engineered to target adhesion factors, which can mobilize persistent leukemic stem cells from the bone marrow niche.

Investigators Look Beyond Immune Checkpoint Inhibitors to Chase Moving Targets in Prostate Cancer

March 16th 2022

Immune checkpoint inhibitors represent only one area of effective therapy for patients with advanced prostate cancer, but they are not “be all, end all” of immunotherapy options.

HER2 Expression Drives Treatment Decisions in Gastric/Esophageal Cancers

March 14th 2022

Experts in the field of upper gastrointestinal cancers discuss recent data from the European Society for Medical Oncology Congress 2021 that may bolster the uptake of HER2 as a guide for treatment decisions in the second line.

Folding CAR T-cell Therapy Into Relapsed/Refractory MCL Treatment

March 9th 2022

Treatment with the CD19-directed CAR T-cell therapy brexucabtagene autoleucel demonstrated significant activity, marked by high response rates and prolonged survival, in patients with relapsed mantle cell lymphoma in the pivotal ZUMA-2 trial.